Cobicistat/Emtricitabine/Elvitegravir/Tenofovir Alafenamide (Genvoya, E/C/F/TAF)

The Latest

This Week in HIV Research: I Screen, You Screen, We All Screen for HPV-Related Cancers

May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

By Barbara Jungwirth and Myles Helfand

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors

This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

By Martha Kempner

This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

By Barbara Jungwirth and Myles Helfand

Switching to Genoya Plus Prezista Maintains Viral Suppression, Improves Renal Markers

Switching from a suppressive five-drug regimen to Genvoya and Prezista proved virologically noninferior to maintaining the initial regimen at 24 weeks and virologically superior at 48 weeks.

By Mark Mascolini

Integrase Inhibitors and Their Effectiveness and Safety in Women

Results from two studies show that not only do integrase inhibitor-based regimens work well in women, but that they better tolerated than a regimen based on the protease inhibitor atazanavir.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

FDA Approved Changes to the Genvoya Label

FDA recently approved changes to the Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) fixed-dose combination tablet product labeling.

By U.S. Food and Drug Administration

Genvoya Approved in Canada: What You Need to Know

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is a complete treatment in one pill that comes in the form of green capsule-shaped tablets. The dose of Genvoya used by adults with HIV is one tablet once daily with food.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

What's the Effect of Genvoya, the Newest Single-Tablet Regimen, on Older Adults Living With HIV?

In this interview, Eric Daar, M.D. discusses how the new coformulation elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya) measures up to its predecessor, specifically among older adults.

By Olivia G. Ford